|1.||Rhim, Hyewhon: 4 articles (09/2014 - 03/2010)|
|2.||Fone, Kevin C F: 4 articles (10/2012 - 12/2003)|
|3.||Schechter, Lee E: 4 articles (02/2011 - 02/2009)|
|4.||Hagan, Jim J: 4 articles (06/2008 - 04/2004)|
|5.||Yun, Hyung-Mun: 3 articles (09/2015 - 03/2010)|
|6.||Borsini, Franco: 3 articles (07/2015 - 07/2011)|
|7.||Meneses, Alfredo: 3 articles (01/2014 - 07/2005)|
|8.||Kitajima, Tsuyoshi: 3 articles (01/2012 - 07/2010)|
|9.||Iwata, Nakao: 3 articles (01/2012 - 07/2010)|
|10.||Kishi, Taro: 3 articles (01/2012 - 07/2010)|
|1.||Schizophrenia (Dementia Praecox)
04/01/2002 - "Thus, this specific 5-HT(6) receptor antagonist was associated with a clear positive outcome in only one model for the positive symptoms of schizophrenia, and had no beneficial effect in the model for negative symptoms. "
09/01/2005 - "5-HT(6) receptor antagonists improved performance in the attentional set shifting task and may have therapeutic potential in the treatment of disorders where cognitive deficits are a feature, including schizophrenia."
01/01/2015 - "5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia."
05/01/2013 - "Nevertheless, little is known about the potential efficacy of 5-HT6 receptor agonists in models of schizophrenia-like cognitive deficits. "
01/01/2012 - "We conducted an association study of the 5-HT6 receptor gene (HTR6) in Japanese patients with schizophrenia (n = 836) and controls (n = 857). "
|2.||Alzheimer Disease (Alzheimer's Disease)
12/01/2009 - "Antagonists of the 5-HT(6) receptor improve cognitive performance in a number of preclinical models and have recently been found to be effective in Alzheimer's disease patients. "
11/01/2014 - "Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial."
01/01/2014 - "Clinical and preclinical studies have supported the notion that using 5-HT6 receptor antagonists is a promising component in the treatment of cognitive dysfunctions associated with aging and Alzheimer's disease. "
05/31/2002 - "Association study of the 5-hydroxytryptamine(6) receptor gene in Alzheimer's disease."
12/03/2015 - "The 5-HT6 receptor (5-HT6R) is almost exclusively expressed in the brain and has emerged as a promising target for cognitive disorders, including Alzheimer's disease. "
|3.||Memory Disorders (Memory Loss)
10/01/2015 - "We evaluated the effects of 5-HT6 receptor antagonists on the memory deficits associated with neuropathy. "
12/01/2003 - "Accumulating evidence suggests a potential role for the 5-HT(6 )receptor in cognitive function and the potential use of 5-HT(6) receptor antagonists in the treatment of learning and memory disorders. "
06/01/2002 - "The possible role of 5-HT(6) receptor antagonists in the treatment of learning and memory disorders has stimulated significant recent work in this area. "
01/01/2000 - "This interaction predicts a possible role for 5-ht6 receptor antagonists in the treatment of learning and memory disorders. "
10/01/2015 - "5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids."
|4.||Amnesia (Dissociative Amnesia)
12/16/2008 - "Herein evidence from studies involving expression of 5-HT(1A), 5-HT(2A), 5-HT(4), and 5-HT(6) receptors in memory formation, amnesia conditions (e.g., pharmacological models or aging) and recovery of memory is reviewed. "
01/01/2011 - "At the present, it is unclear why 5-HT6 receptor agonists and antagonists may facilitate memory or may reverse amnesia in some memory tasks. "
01/01/2011 - "5-HT6 receptor memory and amnesia: behavioral pharmacology--learning and memory processes."
09/01/2014 - "One potential mechanism underlying both the antidepressant and amnesia effect of ECS may involve the regulation of serotonin (5-hydroxytryptamine) 6 (5-HT6) receptor, but less is known about the effects of acute ECS on the changes in 5-HT6 receptor expression in the hippocampus. "
01/01/2010 - "Time-course of 5-HT(6) receptor mRNA expression during memory consolidation and amnesia."
|5.||Central Nervous System Diseases (CNS Diseases)
07/22/2010 - "Though the role of this receptor in many CNS diseases is widely anticipated, lack of definite progress in the development of 5-HT(6) receptor-oriented drugs indicates a need for further discoveries of novel chemotypes with high potency and high selectivity to the receptor. "
09/01/2010 - "Four molecular descriptors were selected from a pool of variables using genetic algorithm, and then used to built a QSAR model for a series of 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT(6) receptor agonists or antagonists, useful for the treatment of central nervous system disorders. "
09/01/2013 - "The exclusive distribution of 5-HT6 receptor in the brain regions and high affinity for antipsychotic and antidepressant drugs makes 5-HT6 receptor a promising target in treatment of CNS diseases. "
11/11/2010 - "As part of our efforts to develop agents for CNS diseases, we have been focused on the 5-HT(6) receptor in order to identify potent and selective ligands for cognitive enhancement. "
05/01/2009 - "As part of our continuing efforts to identify therapeutics for CNS diseases, such as schizophrenia and Alzheimer's disease (AD), we have been focused on the 5-HT(6) receptor in an attempt to identify ligands as a potential treatment for cognitive dysfunction. "
|1.||Serotonin (5 Hydroxytryptamine)
|3.||Dizocilpine Maleate (Dizocilpine)
|4.||Neurotransmitter Agents (Neurotransmitter)
|7.||Dihydrotachysterol (AT 10)
|9.||N- (2,5- dibromo- 3- fluorophenyl)- 4- methoxy- 3- piperazin- 1- ylbenzenesulfonamide
|10.||Messenger RNA (mRNA)